Related Experiment Videos
[A case of eosinophilic cystitis]
Sumihiro Maeda1, Tadashi Hatayama
1Department of Urology, Takatsuki Red Cross Hospital.
Hinyokika Kiyo. Acta Urologica Japonica
|December 21, 2002
Summary
A patient with superficial bladder cancer developed eosinophilic cystitis after treatment. Steroid administration successfully improved bladder symptoms, indicating a potential treatment pathway.
Area of Science:
- Urology
- Oncology
- Pathology
Background:
- Superficial bladder cancer treatment involves transurethral resection and intravesical chemotherapy.
- Pirarubicin hydrochloride is an anthracycline antibiotic used in bladder cancer treatment.
Observation:
- A 67-year-old male patient presented with urinary frequency (pollakisuria) and pain during urination (miction pain).
- Following treatment for superficial bladder cancer, urinalysis showed a significant increase in eosinophilic cells.
- Cystoscopy revealed bladder lesions characterized by ischemia and hypervascularity.
Findings:
- Histological examination of bladder biopsy specimens confirmed the diagnosis of eosinophilic cystitis.
- The observed bladder lesions were consistent with drug-induced or inflammatory changes.
Implications:
- Eosinophilic cystitis can be a complication of superficial bladder cancer treatment, specifically after Pirarubicin hydrochloride instillation.
- Steroid therapy appears effective in managing the symptoms of eosinophilic cystitis in this context.
- Further research is warranted to understand the mechanisms and optimize management of this treatment-related complication.